Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 673470

Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease

Anghel, Rodica; Bachamann, Alexander; Beksac, Meral; Brodowicz, Thomas; Finek, Jindrich; Komadina, Radko; Krzemieniecki, Krzysztof; Lang, Istvan; Marencak, Jozef; Von Moos, Roger et al.
Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease // Wiener klinische Wochenschrift, 125 (2013), 15/16; 439-447 doi:10.1007/s00508-013-0385-4 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 673470 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease

Autori
Anghel, Rodica ; Bachamann, Alexander ; Beksac, Meral ; Brodowicz, Thomas ; Finek, Jindrich ; Komadina, Radko ; Krzemieniecki, Krzysztof ; Lang, Istvan ; Marencak, Jozef ; Von Moos, Roger ; Pechersttorfer, Martin ; Rordorf, Tamara ; Vrbanec, Damir ; Zielinski, Christoph

Izvornik
Wiener klinische Wochenschrift (0043-5325) 125 (2013), 15/16; 439-447

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
anti-resorptive agents; breast cancer; bone metastases

Sažetak
Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA

Projekti:
108-1080058-0046 - KARCINOM DOJKE-MOLEKULARNE,GENETSKE I KLINIČKE KARAKTERISTIKE (Vrbanec, Damir, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Profili:

Avatar Url Damir Vrbanec (autor)

Poveznice na cjeloviti tekst rada:

doi link.springer.com

Citiraj ovu publikaciju:

Anghel, Rodica; Bachamann, Alexander; Beksac, Meral; Brodowicz, Thomas; Finek, Jindrich; Komadina, Radko; Krzemieniecki, Krzysztof; Lang, Istvan; Marencak, Jozef; Von Moos, Roger et al.
Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease // Wiener klinische Wochenschrift, 125 (2013), 15/16; 439-447 doi:10.1007/s00508-013-0385-4 (međunarodna recenzija, članak, znanstveni)
Anghel, R., Bachamann, A., Beksac, M., Brodowicz, T., Finek, J., Komadina, R., Krzemieniecki, K., Lang, I., Marencak, J. & Von Moos, R. (2013) Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wiener klinische Wochenschrift, 125 (15/16), 439-447 doi:10.1007/s00508-013-0385-4.
@article{article, author = {Anghel, Rodica and Bachamann, Alexander and Beksac, Meral and Brodowicz, Thomas and Finek, Jindrich and Komadina, Radko and Krzemieniecki, Krzysztof and Lang, Istvan and Marencak, Jozef and Von Moos, Roger and Pechersttorfer, Martin and Rordorf, Tamara and Vrbanec, Damir and Zielinski, Christoph}, year = {2013}, pages = {439-447}, DOI = {10.1007/s00508-013-0385-4}, keywords = {anti-resorptive agents, breast cancer, bone metastases}, journal = {Wiener klinische Wochenschrift}, doi = {10.1007/s00508-013-0385-4}, volume = {125}, number = {15/16}, issn = {0043-5325}, title = {Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease}, keyword = {anti-resorptive agents, breast cancer, bone metastases} }
@article{article, author = {Anghel, Rodica and Bachamann, Alexander and Beksac, Meral and Brodowicz, Thomas and Finek, Jindrich and Komadina, Radko and Krzemieniecki, Krzysztof and Lang, Istvan and Marencak, Jozef and Von Moos, Roger and Pechersttorfer, Martin and Rordorf, Tamara and Vrbanec, Damir and Zielinski, Christoph}, year = {2013}, pages = {439-447}, DOI = {10.1007/s00508-013-0385-4}, keywords = {anti-resorptive agents, breast cancer, bone metastases}, journal = {Wiener klinische Wochenschrift}, doi = {10.1007/s00508-013-0385-4}, volume = {125}, number = {15/16}, issn = {0043-5325}, title = {Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease}, keyword = {anti-resorptive agents, breast cancer, bone metastases} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.